{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:48:51Z","timestamp":1791931731743,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s00223-008-9145-2","type":"journal-article","created":{"date-parts":[[2008,6,4]],"date-time":"2008-06-04T23:41:02Z","timestamp":1212622862000},"page":"418-426","source":"Crossref","is-referenced-by-count":41,"title":["The Effects of Alendronate Treatment in Osteoporotic Patients Affected by Monoclonal Gammopathy of Undetermined Significance"],"prefix":"10.1007","volume":"82","author":[{"given":"Jessica","family":"Pepe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia","family":"Mascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Piemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Fassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,6,6]]},"reference":[{"key":"9145_CR1","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TR, Rajkumar SV, Karson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ III (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362\u20131369","journal-title":"N Engl J Med"},{"key":"9145_CR2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","volume":"19","author":"LJ Melton III","year":"2004","unstructured":"Melton LJ III, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA (2004) Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 19:25\u201330","journal-title":"J Bone Miner Res"},{"key":"9145_CR3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","volume":"135","author":"H Gregersen","year":"2006","unstructured":"Gregersen H, Jensen P, Gislum M, Jorgensen B, Sorensen HT, Norgaard M (2006) Fracture risk in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 135:62\u201367","journal-title":"Br J Haematol"},{"key":"9145_CR4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","volume":"134","author":"J Pepe","year":"2006","unstructured":"Pepe J, Petrucci MT, Nofroni I, Fassino V, Diacinti D, Romagnoli E, Minisola S (2006) Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol 134:485\u2013490","journal-title":"Br J Haematol"},{"key":"9145_CR5","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood.V90.9.3743","volume":"90","author":"M Pecherstorfer","year":"1997","unstructured":"Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, Sagaster P, Kohn H, Bayer P, Thiebaud D, Ludwig H (1997) Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 90:3743\u20133750","journal-title":"Blood"},{"key":"9145_CR6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0609.1997.tb00932.x","volume":"58","author":"T Vejlgaard","year":"1997","unstructured":"Vejlgaard T, Abildgaard N, Jans H, Nielsen JL, Heickendorff L (1997) Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analysis of type I collagene telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagenes. Eur J Haematol 58:104\u2013108","journal-title":"Eur J Haematol"},{"key":"9145_CR7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1445-5994.2001.00055.x","volume":"31","author":"T Diamond","year":"2001","unstructured":"Diamond T, Levy S, Smith A, Day P, Manoharan A (2001) Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Intern Med J 31:272\u2013278","journal-title":"Intern Med J"},{"key":"9145_CR8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2002.00505.x","volume":"69","author":"C Jakob","year":"2002","unstructured":"Jakob C, Zavrski I, Heider U, Brux B, Eucker J, Langelotz C, Sinha P, Possinger K, Sezer O (2002) Bone resorption parameters carboxy-terminal telopeptide of type I collagen (ICTP), amino-terminal collagen type I telopeptide (NTx), and deoxypyridinoline (DpD) in MGUS and multiple myeloma. Eur J Haematol 69:37\u201342","journal-title":"Eur J Haematol"},{"key":"9145_CR9","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","volume":"87","author":"R Bataille","year":"1996","unstructured":"Bataille R, Chappard D, Basle MF (1996) Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 87:4762\u20134769","journal-title":"Blood"},{"key":"9145_CR10","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A (2003) Soluble receptor activator of nuclear factor-kappa B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102:1064\u20131069","journal-title":"Blood"},{"key":"9145_CR11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","volume":"126","author":"M Politou","year":"2004","unstructured":"Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A (2004) Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1\u03b1) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 126:686\u2013689","journal-title":"Br J Haematol"},{"key":"9145_CR12","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"9145_CR13","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"9145_CR14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:330\u2013340","journal-title":"N Engl J Med"},{"key":"9145_CR15","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","volume":"20","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS (2002) American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719\u20133736","journal-title":"J Clin Oncol"},{"key":"9145_CR16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0169-6009(08)80095-5","volume":"23","author":"S Minisola","year":"1993","unstructured":"Minisola S, Pacitti MT, Scarda A, Rosso R, Romagnoli E, Carnevale V, Scarnecchia L, Mazzuoli GF (1993) Serum ionized calcium, parathyroid hormone and related variables: effects of age and sex. Bone Miner 23:183\u2013193","journal-title":"Bone Miner"},{"key":"9145_CR17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"9145_CR18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/clinchem\/39.3.529","volume":"39","author":"BW Hollis","year":"1993","unstructured":"Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL (1993) Determination of vitamin D status by radioimmunoassay with 125I labeled tracer. Clin Chem 39:529\u2013533","journal-title":"Clin Chem"},{"key":"9145_CR19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00198-004-1757-4","volume":"16","author":"J Pepe","year":"2005","unstructured":"Pepe J, Romagnoli E, Nofroni I, Pacitti MT, De Geronimo S, Letizia C, Tonnarini G, Scarpiello A, D\u2019Erasmo E, Minisola S (2005) Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int 16:805\u2013812","journal-title":"Osteoporos Int"},{"key":"9145_CR20","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","volume":"44","author":"C Rosenquist","year":"1998","unstructured":"Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C (1998) Serum CrossLaps one step ELISA. First application of monoclonal antibodies for measurement of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281\u20132289","journal-title":"Clin Chem"},{"key":"9145_CR21","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/clinchem\/41.11.1560","volume":"41","author":"B Gomez Jr","year":"1995","unstructured":"Gomez B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT (1995) Monoclonal antibody assay for measuring bone specific alkaline phosphatase activity in serum. Clin Chem 41:1560\u20131566","journal-title":"Clin Chem"},{"key":"9145_CR22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/PL00005815","volume":"64","author":"S Minisola","year":"1999","unstructured":"Minisola S, Pacitti MT, Romagnoli E, Rosso R, Carnevale V, Caravella P, Scillitani A, Dicembrino F (1999) Clinical validation of a new immunoradiometric assay for intact human osteocalcin. Calcif Tissue Int 64:365\u2013369","journal-title":"Calcif Tissue Int"},{"key":"9145_CR23","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/clinchem\/43.11.2076","volume":"43","author":"M Karmatschek","year":"1997","unstructured":"Karmatschek M, Maier I, Seibel MJ, Woitge HW, Ziegler R, Armbruster FP (1997) Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin Chem 43:2076\u20132082","journal-title":"Clin Chem"},{"key":"9145_CR24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"9","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 9:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"9145_CR25","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137\u20131141","journal-title":"J Bone Miner Res"},{"key":"9145_CR26","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Melton LJ III (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761\u20131767","journal-title":"Lancet"},{"key":"9145_CR27","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/jbmr.5650110719","volume":"11","author":"TW O\u2019Neill","year":"1996","unstructured":"O\u2019Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010\u20131018","journal-title":"J Bone Miner Res"},{"key":"9145_CR28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","volume":"11","author":"HK Genant","year":"1996","unstructured":"Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis the Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984\u2013996","journal-title":"J Bone Miner Res"},{"key":"9145_CR29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4065\/75.9.888","volume":"75","author":"TM Vogt","year":"2000","unstructured":"Vogt TM, Ross PD, Palermo L, Musliner T, Genant HK, Black D, Thompson DE (2000) Vertebral fracture prevalence among women screened for the Fracture Intervention Trial and a simple clinical tool to screen for undiagnosed vertebral fractures. Fracture Intervention Trial Research Group. Mayo Clin Proc 75:888\u2013896","journal-title":"Mayo Clin Proc"},{"key":"9145_CR30","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1056\/NEJMc070145","volume":"356","author":"S Minisola","year":"2007","unstructured":"Minisola S, Pepe J, Romagnoli E (2007) Monoclonal gammopathy of undetermined significance. N Engl J Med 356:2223\u20132224","journal-title":"N Engl J Med"},{"key":"9145_CR31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","volume":"9","author":"HA Pols","year":"1999","unstructured":"Pols HA, Felsenberg D, Hanley DA, Stepan J, M\u0169noz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461\u2013468","journal-title":"Osteoporos Int"},{"key":"9145_CR32","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Br\u00f6ll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsh LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 333:1437\u20131443","journal-title":"N Engl J Med"},{"key":"9145_CR33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604\u2013610","journal-title":"N Engl J Med"},{"key":"9145_CR34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428199809059252","volume":"32","author":"MV Dhodapkar","year":"1998","unstructured":"Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC, Barlogie B (1998) Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma 32:121\u2013127","journal-title":"Leuk Lymphoma"},{"key":"9145_CR35","first-page":"1693","volume":"79","author":"P Garnero","year":"1994","unstructured":"Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693\u20131700","journal-title":"J Clin Endocrinol Metab"},{"key":"9145_CR36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1017\/S0007114599000987","volume":"81","author":"E Romagnoli","year":"1999","unstructured":"Romagnoli E, Caravella P, Scarnecchia L, Martinez P, Minisola S (1999) Hypovitaminosis D in an Italian population of healthy subjects and hospitalized patients. Br J Nutr 81:133\u2013137","journal-title":"Br J Nutr"},{"key":"9145_CR37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(95)91266-5","volume":"346","author":"RP Wielen van der","year":"1995","unstructured":"van der Wielen RP, Lowik MR, van den Berg H, de Groot LC, Haller J, Moreiras O, van Staveren WA (1995) Serum vitamin D concentrations among elderly people in Europe. Lancet 346:207\u2013210","journal-title":"Lancet"},{"key":"9145_CR38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","volume":"17","author":"H Dobnig","year":"2006","unstructured":"Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A (2006) Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17:693\u2013703","journal-title":"Osteoporos Int"},{"key":"9145_CR39","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","volume":"15","author":"JJ Body","year":"2006","unstructured":"Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 15:1221\u20131228","journal-title":"Clin Cancer Res"},{"key":"9145_CR40","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3109\/10428190309178778","volume":"44","author":"P Musto","year":"2003","unstructured":"Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, Scalzulli PR, Dell\u2019Olio M, La Sala A, Mantuano S, Nobile M, Carella AM (2003) Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma 44:1545\u20131548","journal-title":"Leuk Lymphoma"},{"key":"9145_CR41","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","volume":"42","author":"MC Hochberg","year":"1999","unstructured":"Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246\u20131254","journal-title":"Arthritis Rheum"},{"key":"9145_CR42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","volume":"85","author":"RD Wasnich","year":"2000","unstructured":"Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231\u2013236","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-008-9145-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-008-9145-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-008-9145-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T02:31:04Z","timestamp":1709001064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-008-9145-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["9145"],"URL":"https:\/\/doi.org\/10.1007\/s00223-008-9145-2","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}